ENTRY       D10600            Mixture   Drug
NAME        Dolutegravir, abacavir and lamivudine;
            Triumeq (TN)
PRODUCT     ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE (ViiV Healthcare Company)
COMPONENT   (Dolutegravir sodium [DR:D10113] | Dolutegravir [DR:D10066]), Abacavir sulfate [DR:D00891], Lamivudine [DR:D00353]
CLASS       Antiviral
             DG03107  Anti-HIV agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
              DG03183  UGT1A1 substrate
            Transporter inhibitor
             DG02863  SLC22A2 inhibitor
             DG02864  SLC47A1 inhibitor
REMARK      Therapeutic category: 6250
            ATC code: J05AR13
            Product: D10600<JP/US>
EFFICACY    Antiviral
  DISEASE   HIV-1 infection [DS:H01563]
COMMENT     Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A4.
            Dolutegravir is an inhibitor of OCT2 and MATE1.
TARGET      HIV-1 reverse transcriptase [KO:K24802]
            HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24802+K24803)  Viral genome structure
            ko03240(K24802+K24803)  Viral replication
            ko03250(K24802+K24803)  Viral life cycle - HIV-1
METABOLISM  Enzyme: UGT1A1 [HSA:54658]; CYP3A4 [HSA:1576]
INTERACTION Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AR Antivirals for treatment of HIV infections, combinations
                 J05AR13 Lamivudine, abacavir and dolutegravir
                  D10600  Dolutegravir, abacavir and lamivudine &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Combinations
               Abacavir Sulfate/ Dolutegravir/ Lamivudine
                D10600  Dolutegravir, abacavir and lamivudine
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10600  Dolutegravir, abacavir and lamivudine
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               D10600  Dolutegravir, abacavir and lamivudine
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10600  Dolutegravir, abacavir and lamivudine
              DG02924  UGT substrate
               DG03183  UGT1A1 substrate
                D10600  Dolutegravir, abacavir and lamivudine
             Transporter inhibitor
              DG02863  SLC22A2 inhibitor
               D10600  Dolutegravir, abacavir and lamivudine
              DG02864  SLC47A1 inhibitor
               D10600  Dolutegravir, abacavir and lamivudine
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D10600  Dolutegravir, abacavir and lamivudine
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D10600  Dolutegravir, abacavir and lamivudine &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10600
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10600
             Drug transporters
              D10600
DBLINKS     PubChem: 254741562
///
